Author

Colin D. Mansfield

AB Science (France)ORCID 0000-0001-9175-5051Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1 Organism:rat· 1 Approach:statistical model· 1

Frequent Co-Authors

Alain Moussy· 3 shared Laurent GrosiD· 2 shared Olivier HermineiD· 2 shared Patrick VermerschiD· 2 shared Abdellah Benjahad· 1 shared Armelle GoubardiD· 1 shared Benoı̂t GigantiD· 1 shared Bérengère Hajem· 1 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersNeuroscience

Alain Moussy

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

NeurosciencebioRxivPreprintJul 7, 2026

Masitinib is an oral, brain penetrant inhibitor of microglial and mast cell activity with neuroprotective potential in progressive forms of multiple sclerosis

Patrick Vermersch, Alain Moussy, Colin D. Mansfield, Olivier Hermine

This paper demonstrates that masitinib achieves sufficient CNS concentrations to inhibit key targets in progressive MS, showing neuroprotective effects and potential as a treatment.

DOI 10.64898/2026.07.02.735783

ratexperimental assay

𝕏 PostBluesky

Cell BiologybioRxivPreprintDec 12, 2025

Identification of AB8939, a novel synthetic microtubule destabilizer and ALDH inhibitor that overcomes multidrug resistance in tumor cells as a drug candidate for the treatment of refractory acute myeloid leukemia

Martine Humbert, Sébastien Letard, Armelle Goubard…·Patrice C. Dubreuil

This paper identifies AB8939, a novel drug that targets microtubules and ALDH enzymes, showing efficacy against drug-resistant AML cells and models.

1 citation

humanexperimental assay

𝕏 PostBluesky

NeurosciencePLoS ONEPeer-reviewedMay 14, 2025

Masitinib Limits Neuronal Damage, as Measured by Serum Neurofilament Light Chain Concentration, in a Model of Neuroimmune-Driven Neurodegenerative Disease

Olivier Hermine, Laurent Gros, Truong-An Tran…·Patrick Vermersch

2 citations

mousestatistical model

𝕏 PostBluesky